Leuprorelin - DURECT/Curaxis

Drug Profile

Leuprorelin - DURECT/Curaxis

Alternative Names: DURIN™ leuprolide implant; DURIN™-leuprolide; Leuprorelin - Curaxis/DURECT; Leuprorelin - DURECT/Voyager; Leuprorelin - Voyager/DURECT; Memryte implant; VP4896

Latest Information Update: 27 Sep 2010

Price : $50

At a glance

  • Originator DURECT Corporation; Voyager Pharmaceutical
  • Developer Curaxis Pharmaceutical Corporation
  • Class Antineoplastics; Gonadotropins; Infertility therapies; Oligopeptides; Pituitary hormone releasing hormones
  • Mechanism of Action Gonadotropin releasing hormone stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Suspended Alzheimer's disease

Most Recent Events

  • 15 Mar 2016 Biomarkers information updated
  • 23 Sep 2010 Curaxis enters into an equity line agreement with Southridge Partners
  • 19 Aug 2010 Voyager Pharmaceutical completes reverse merger and becomes publicly traded company called Curaxis Pharmaceutical Corporation; funding secured to resume clinical development of leuprolin
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top